The triple-negative subtype of breast cancer, which often includes the Claudin-low subtype [4], lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, presents a particularly difficult therapeutic challenge as this subtype is characterized by its aggressive nature and lack of targeted therapies [5, 6]. This evidence concerns the gene ERBB2 and breast cancer.